2022 AACE Diabetes Guideline Update
aace diabetes guideline

September 27, 2022

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

This is the updated guideline for the care and management of people with or at risk for diabetes mellitus. The guideline features 170 updated and new evidence-based clinical practice recommendations for diabetes at every stage, including prevention, diagnosis, and treatment.

Read the full guideline here.

Our guideline addresses a variety of new topics related to management of diabetes, including COVID-19 vaccination, telehealth, social determinants of health, male and female infertility, secondary diabetes, and nutritional supplements. Additionally, the 2022 guideline includes expanded sections on management of hyperglycemia in the hospital setting and hypoglycemia, quality of life recommendations on sleep hygiene and depression, and updated safety-oriented recommendations on occupational risk and risk of cancer.

The 2022 guideline update synthesizes thousands of articles to provide health care professionals with the latest evidence-based information on the total care of diabetes. Particularly important updates of this guideline include the following: 

  • Complications-centric recommendations for the use of pharmacotherapy for the management of persons with diabetes
  • Based on the latest landmark cardiovascular outcome trials, the guideline covers the use of newer antihyperglycemic therapies with enhanced safety and classes of drugs that reduce the risk of cardiovascular disease, heart failure and/or chronic kidney disease, independent of glycemic control.
  • To improve glycemia and address the risk or presence of cardiometabolic complications, this guideline also provides recommendations for FDA-approved weight-loss medications and comprehensive guidance on the management of obesity, which is a cornerstone of care of persons with diabetes.
  • Recommendations for management of comorbidities and complications, including obesity, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic/chronic kidney disease and cardiovascular disease.

The writing team of nearly 30 experts was led by co-chairs Drs. Lawrence Blonde and Guillermo Umpierrez and section leaders Drs. Sethu Reddy and Janet McGill.

 

The guideline will be discussed in-person during sessions at our AACE Cardiometabolic Conference. Join us in San Antonio September 30 - October 2!